108
Participants
Start Date
July 22, 2022
Primary Completion Date
February 17, 2025
Study Completion Date
February 17, 2025
Pamiparib
40mg PO. bid.
Bevacizumab
7.5mg/kg IV. D1 (q3w.)
Tislelizumab
200mg IV. D1
Nab paclitaxel
125mg / m2 IV. D1, 8 (q3w).
Bevacizumab + Nab paclitaxel (intense dose-dense)
Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hubei Cancer Hospital
OTHER
Union Hospital, Tongji Medical College
UNKNOWN
Peking University Cancer Hospital & Institute
OTHER
Anhui Provincial Hospital
OTHER_GOV
Sun Yat-sen University Cancer Center (SUSUCC)
UNKNOWN
Shandong Cancer Hospital and Institute
OTHER
The First Affiliated Hospital of Xi 'an Jiaotong University
UNKNOWN
Fujian Cancer Hospital
OTHER_GOV
Chongqing University Cancer Hospital
OTHER
Qilu Hospital of Shandong University
OTHER
Tongji Hospital
OTHER